Kolon Life Science Inc. (KOSDAQ:102940)

South Korea flag South Korea · Delayed Price · Currency is KRW
30,100
-2,150 (-6.67%)
Jul 20, 2026, 3:30 PM KST
Market Cap394.03B -9.3%
Revenue (ttm)213.81B +27.5%
Net Income35.33B
EPS2,498.04
Shares Out 13.09M
PE Ratio12.05
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume101,099
Open31,000
Previous Close32,250
Day's Range29,150 - 32,900
52-Week Range27,600 - 72,700
Beta0.06
Analystsn/a
Price Targetn/a
Earnings DateAug 13, 2026

About Kolon Life Science

Kolon Life Science Inc., a biotechnology company, develops cell and gene therapy products. The company is developing KLS-2031, a product candidate in Phase 1 clinical trials for use in the treatment of neuropathic pain; and KLS-3021, a oncolytic viral therapy in pre-clinical development. It also provides active pharmaceutical ingredients and pharmaceutical intermediates; offers CDMO and CMO services; and supplies pyrithione antimicrobial for use in personal care and industrials products. The company was formerly known as Korea Tissuegene Asia, ... [Read more]

Industry Chemicals
Sector Materials
Founded 2000
Employees 425
Stock Exchange KOSDAQ
Ticker Symbol 102940
Full Company Profile

Financial Performance

Financial Statements